: Verve Therapeutics’ stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment
Analysts raise concerns about comparative effectiveness of experimental cholesterol treatment.
Analysts raise concerns about comparative effectiveness of experimental cholesterol treatment.